Dr Agarwals Eye Hospital working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

105.15×	98.00×	79.95×	69.75×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
12.67×	12.36×	13.17×	12.80×
—	—	—	317.53×
—	—	—	−234.98×
18.72×	−12.79×	−15.25×	−31.37×
0.68×	0.72×	0.72×	0.76×
—	1.73×	1.94×	1.89×
—	0.80×	0.99×	0.93×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health

₹ CrorePeersKMCSHIL KOVAI LOTUSEYE GPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMEDMcap ₹2,527 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Inventory Days (DIO)	69.75	79.95	98.00	105.15
Receivable Days (DSO)	12.80	13.17	12.36	12.67
Payable Days (DPO)	317.53	—	—	—
Cash Conversion Cycle (days)	-234.98	—	—	—
Working Capital Turnover	-31.37	-15.25	-12.79	18.72
Asset Turnover	0.76	0.72	0.72	0.68
Cash Conversion (CFO/Net Income)	1.89	1.94	1.73	—
CFO/EBITDA	0.93	0.99	0.80	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.